Clinical Trial Update: The Myocet/Lapatinib Study. ICORG 10-03, V5 [Phase 1, Phase 2]

View source ↗

Summary

This update notes the termination of ICORG 10-03, a Phase 1/2 study of Myocet in combination with lapatinib for HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Lapatinib)
• Myocet (liposomal doxorubicin)

Snippet

Sponsor: Cancer Trials Ireland | Conditions: Her2 Positive Metastatic Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED